Therapeutic approaches to bulimia nervosa

Bibliography

• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (4th edition). American Psychiatric Association, Washington DC, USA (1994).
   Google Scholar
• HAY PJ, BACALTCHUK J: Psychotherapy for bulimia nervosa and binging (Cochrane Review). In: The Cochrane Library, Issue 2, 2000. Update Software, Oxford (2000).
   Google Scholar
• PETERSON CB, MITCHELL JE: Psychosocial and pharma-cological treatment of eating disorders: a review of research findings. J. Clin. Psycho]. (1999) 55:685–697.
   Google Scholar
• FREEMAN C: Drug treatment for bulimia nervosa. Neuropsychobiology (1998) 37:72–79.
   PubMed Web of Science ®Google Scholar
• ••A review of currently available drugs and their effects inbulimia nervosa.
   Google Scholar
• KRUGER S, KENNEDY SH: Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder. J. Psychiatr. Neurosci. (2000) 25:497–508.
   PubMed Web of Science ®Google Scholar
• HALFORD JCG, BLUNDELL JE: Pharmacology of appetite suppression. Progess Drug Res. (2000) 54:25–58.
   PubMedGoogle Scholar
• ••A very comprehensive review on possible targets forappetite suppression.
   Google Scholar
• WOLFE BE, METZGER ED, JIMERSON DC: Research update on serotonin function in bulimia nervosa and anorexia nervosa. PsychopharmacoL Bull. (1997) 33:345–354.
   PubMed Web of Science ®Google Scholar
• MERTENS IL, VAN GAAL LF: Promising new approaches to the management of obesity. Drugs (2000) 60:1–9.
   PubMedGoogle Scholar
• •A thorough review of the pathophysiology of obesity.
   Google Scholar
• DUNLOP J, ROSENZWEIG-LIPSON S: Therapeutic approaches to obesity. Exp. Opin. Ther. Patents (1998) 8:1683-1694. A comprehensive review of patents related to the treatment of obesity.
   Google Scholar
• KAYE W, GENDALL K, STROBER M: Serotonin function and selective serotonin reuptake inhibitor treatment in anorexia nervosa and bulimia nervosa. Biol. Psychiatry (1998) 44:812–824.
   PubMedGoogle Scholar
• LEIBOWITZ SF, ALEXANDER JT: Hypothalamic serotonin in control of eating behavior, meal size and body weight. Biol. Psychiatry (1998) 44:851–864.
   PubMed Web of Science ®Google Scholar
• DE VRY J, SCHREIBER R: Effects of selected serotonin 5-HT1 and 5-HT2 receptor agonists on feeding behavior: possible mechanisms of action. NeuroscL Biobehav. Rev. (2000) 24:341–53.
   PubMed Web of Science ®Google Scholar
• •A very detailed article discussing the role of the various serotonin receptors involved in feeding.
   Google Scholar
• SARGENT PA, SHARPLEY AL, WILLIAMS C, GOODALL EM, COWEN PJ: 5-HT2c receptor activation decreases appetite and body weight in obese subjects. Psycho-pharmacology (1997) 13 3:309–312.
   Google Scholar
• BOELES S, WILLIAMS C, CAMPLING GM, GOODALL EM, COWEN PJ: Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology (1997) 129:179–182.
   PubMed Web of Science ®Google Scholar
• LEVITAN RD, KAPLAN AS, JOFFE RT, LEVITT AJ, BROWN GM: Hormonal and subjective responses to intrave-nous meta-chlorophenylpiperazine in bulimia nervosa. Arch. Gen. Psychiatry (1997) 45:521–527.
   Google Scholar
• SPIGSET 0, ANDERSEN T, HAGG S, MJORNDAL T: Enhanced platelet serotonin 5-HT2A receptor binding in anorexia nervosa and bulimia nervosa. Eur. Neuro-psyhcopharmacology (1999) 9:469–473.
   PubMedGoogle Scholar
• FARIS PL, KIM SW, MELLER WH et al.: Effect of decreasing vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet (2000) 35 5:792–797.
   Google Scholar
• GERETSEGGER C, GREIMEL KV, ROED IS, HESSELINK JM: Ipsapirone in the treatment of bulimia nervosa: an open pilot study. Int. Eat. Disord. (1995) 17:359–363.
   PubMedGoogle Scholar
• STAHL SM: Psychopharmacology of reward and drugs of abuse. In: Essential psychopharmacology, 2ad edition. Cambridge, Cambridge University Press (2000)499–538.
   Google Scholar
• SHOR-POSNER G, AZAR AP, JHANWAR-UNIYAL M, FILART R, LEIBOWITZ SF: Destruction of noradrenergic innervation to the paraventricular nucleus: deficits in food intake, macronutrient selection and compensa-tory eating after food deprivation. Pharmacol. Biochem. Behav. (1986) 25:381–192.
   PubMed Web of Science ®Google Scholar
• TEMPEL DL, LEIBOWITZ SF. Glucocorticoid receptors in PVN: interactions with NE, NPY and Gal in relation to feeding. Am. J Physiol. (1993) 265 :E794–800.
   Google Scholar
• MAURI MC, RUDELLI R, SOMASCHINI E et al.: Neurobio-logical and psychopharmacological basis in the therapy of bulimia and anorexia. Prog. Neuropsycho-pharmacol. Biol. Psychiatry (1996) 20:207–240.
   PubMed Web of Science ®Google Scholar
• •A general review on neurobiological alterations documented in bulimia nervosa.
   Google Scholar
• KAYE WH, BALLENGER JC, LYDIARD RB et al.: CSF mon oamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am. J Psychiatry (1990) 147:225–229.
   PubMed Web of Science ®Google Scholar
• FAVA M, COPERLAND PM, SCHWEIGER U, HERZOG DB:Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Am. J. Psychiatry (1989) 146:963–971.
   PubMed Web of Science ®Google Scholar
• JIMERSON DC, LESEM MD, KAYE WH, BREWERTON TD:Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Arch. Gen. Psychiatry (1992) 49:132–138.
   PubMed Web of Science ®Google Scholar
• HORNE RL, FERGUSON JM, POPE HG, JR. etal: Treatmentof bulimia with bupropion: a multicenter controlled trial. J. Clin. Psychiatry (1988) 49:262–266.
   PubMed Web of Science ®Google Scholar
• KAYE WH, BERETTINI W, GEORGE DT: Altered cerebro-spinal fluid neuropeptide Y and peptide YY immuno-reactivity in anorexia and bulimia nervosa. Arch. Gen. Psychiatry (1990) 47:548–556.
   PubMed Web of Science ®Google Scholar
• GENDALL KA, KAYE WH, ALTEMUS M, McCOHANA CW, LA VIA MC: Izptin, neuropeptide Y and peptide YY in long-term recovered eating disorder patients. Biol. Psychiatry (1999) 4 6 :292–299.
   Google Scholar
• INUI A: Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharacol ScL (1999) 2 0 :43–46.
   Google Scholar
• •A review of the role of neuropeptide Y and its receptors in food intake.
   Google Scholar
• SMAGIN GN, HOWELL LA, RYAN DH, DE SOUZA EB, HARRIS RB: The role of CRF2 receptors in corticotropin-releasing factor and urocortin-induces anorexia. Neuroreport (1998) 11: 1601-1606.
   Google Scholar
• GIRAUDO SQ, BILLINGTON CJ, LEVINE AS: Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands. Brain Res. (1998) 809:302–306.
   PubMed Web of Science ®Google Scholar
• MORAN TH, SCHWARTZ GJ: Neurobiology of cholecys-tokinin. Grit. Rev. Neurobiol. (1994) 9:1–28.
   PubMed Web of Science ®Google Scholar
• GERACIOTI TD Jr, LIDDLE RA: Impaired cholecys-tokinin secretion in bulimia nervosa. N Engl. J Med. (1988) 319:683–688.
   PubMed Web of Science ®Google Scholar
• COLOMBO G, AGABIO R, DIAZ G, LOBINA C, REALI R,GESSA GL: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life ScL (1998) 63 :PL113–117.
   PubMed Web of Science ®Google Scholar
• THIM L, KRISTENSEN P, LARSEN PJ, WULFF BS: CART, anew anorectic peptide. Int. j Biochem. Cell. Biol. (1998) 30:1281–1284.
   PubMedGoogle Scholar
• SINHA D, ADDYA S, MURER E, BODEN G: 15-Deoxy-delta(12,14) prostaglandin J2: a putative endogenous promoter of adipogenesis suppress the ob gene. Metabolism (1999) 48:786–791.
   PubMedGoogle Scholar
• CHINETTI G, FRUCHART JC, STAELS B: Peroxisomeproliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. (2000) 49:497–505.
   PubMed Web of Science ®Google Scholar
• GLASS MJ, BILLINGTON CJ, LEVINE AS: Opioids and food intake: disturbed functional neural pathways? Neuropeptides (1999) 33:360–368.
   PubMed Web of Science ®Google Scholar
• JOHNSON RD: Opioid involvement in feeding behavior and the pathogenesis of certain eating disorders. Med. Hypotheses (1995) 45:491–497.
   PubMed Web of Science ®Google Scholar
• BREWERTON TD, LYDIARD RB, LARAIA MT, SHOOK JE,BALLENGER JC: CSF beta-endorphin and dynorphin in bulimia nervosa. Am. J Psychiatry (1992)149:1086-1090.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(3)
   Google Scholar
• MARRAZZI MA, BACON JP, KINZIE J, LUBY ED: Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int. Olin. Psychopharmacol (1995) 10:163–172.
   PubMed Web of Science ®Google Scholar
• MOLLEREAU C, MOULEDOUS L: Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides (2000) 21:907–917.
   PubMed Web of Science ®Google Scholar
• POLIDORI C, DE CARO G, MASSI M: The hyperphagic effect of nociceptin/orphanin FQ in rats. Peptides (2000) 21:1051–1062.
   PubMed Web of Science ®Google Scholar
• WOLF G: Orexins: a newly discovered family of hypothalamic regulators of food intake. Nutr. Rev. (1998) 56:172–173.
   PubMedGoogle Scholar